Will Big Pharma Dominate the Obesity Space?

Still in the dark about how Obamacare might affect you and your portfolio? The Motley Fool's special report "Everything You Need to Know About Obamacare" takes a 360-degree look at how the law may impact your taxes, health insurance, and investments. Click here to grab your free copy today.

Obesity was the focus of this segment from The Motley Fool's health-care show, Market Checkup. More than 35% of Americans are obese, and obesity can lead to serious health problems, including diabetes, stroke, and heart disease. The AMA also recently classified obesity as an official disease.

In this video, health-care analysts David Williamson and Max Macaluso discuss how two Big Pharma companies -- Novo Nordisk and AstraZeneca  -- might become the next major players in the obesity space.

The article Will Big Pharma Dominate the Obesity Space? originally appeared on Fool.com.

David Williamson and Max Macaluso, Ph.D., have no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story